Pronto disponible para inscripción

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

FiREBOLT: LY4337713 in Adults with FAP-Positive Solid Tumors - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called LY4337713 (the study drug) is a safe and effective option for people who have FAP-positive solid tumors. The study drug is a type of radiotherapy that is intended to target and attach only to FAP. The goal of targeted radiotherapy is to provide selective delivery of radiation doses that can destroy tumor cells.

¿Cuál es la Condición que se está estudiando?

Cancers with Fibroblast Activation Protein (FAP) Positive Solid Tumors

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with one of the following forms of cancer with a solid tumor present: adenocarcinoma of the pancreas, HR-positive & HER2-negative breast cancer, HER2-positive breast cancer, triple-negative breast cancer, platinum-resistant or refractory ovarian cancer, gastric adenocarcinoma, colorectal cancer, squamous cell carcinoma or adenocarcinoma esophageal cancer, or cholangiocarcinoma
Have clinical or imaging evidence of FAP expression

For more information, contact the study team at dana.a.warren@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

Si elige unirse a este estudio, podrá:

Get an intravenous (IV) injection of the study drug either every 4 weeks or every 6 weeks, depending on when you are enrolled
Hacer extracciones de sangre y dar muestras de orina
Realice tomografías computarizadas o resonancias magnéticas de manera regular.

Detalles del Estudio

Título Completo

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)

Investigador Principal